TetraPhase Pharmaceuticals Receives $45,000,000 Series C Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b69345a5-e380-4946-b772-75486e99dd38&Preview=1 - Date
6/1/2010 - Company Name
TetraPhase Pharmaceuticals - Mailing Address
480 Arsenal Street Watertown, MA 02472 - Company Description
Tetraphase Pharmaceuticas is focused on the discovery and development of new tetracycline antibiotics to treat drug resistant bacterial infections. The company’s approach capitalizes on ground-breaking technology, licensed from Harvard University (Dr. Andrew Myers, Professor of Chemistry and Chemical Biology), which enables for the first time the total synthesis of tetracyclines by enabling their synthesis from simple building blocks. The technology allows extensive modification of the core molecule and synthesis of thousands of new tetracycline compounds that were previously inaccessible, dramatically expanding the universe of an existing, highly successful antibiotic class. Tetraphase has an exlusive worldwide license to the technology. - Website
http://www.tphase.com - Transaction Type
Venture Equity - Transaction Amount
$45,000,000 - Transaction Round
Series C - Proceeds Purposes
Proceeds from the Series C financing will be used to advance Tetraphase’s pipeline of novel antibiotics, into Phase 1 and Phase 2 clinical studies. - M&A Terms
- Venture Investor
Excel Venture Management - Venture Investor
Mediphase Venture Partners - Venture Investor
Flagship Ventures - Venture Investor
Skyline Ventures - Venture Investor
CMEA Ventures - Venture Investor
Fidelity BioSciences
